GAMMA Investing LLC Buys 255 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

GAMMA Investing LLC boosted its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 54.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 721 shares of the company’s stock after acquiring an additional 255 shares during the period. GAMMA Investing LLC’s holdings in Dr. Reddy’s Laboratories were worth $53,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. CWM LLC increased its position in shares of Dr. Reddy’s Laboratories by 37.9% during the fourth quarter. CWM LLC now owns 2,174 shares of the company’s stock valued at $151,000 after purchasing an additional 598 shares during the period. Trexquant Investment LP bought a new stake in Dr. Reddy’s Laboratories in the 4th quarter valued at $219,000. Blue Trust Inc. raised its stake in shares of Dr. Reddy’s Laboratories by 77.3% in the 4th quarter. Blue Trust Inc. now owns 3,378 shares of the company’s stock valued at $227,000 after buying an additional 1,473 shares in the last quarter. Team Hewins LLC bought a new position in shares of Dr. Reddy’s Laboratories during the 4th quarter worth about $239,000. Finally, Lindbrook Capital LLC boosted its position in shares of Dr. Reddy’s Laboratories by 19.1% during the 4th quarter. Lindbrook Capital LLC now owns 3,519 shares of the company’s stock valued at $245,000 after acquiring an additional 565 shares in the last quarter. Institutional investors and hedge funds own 14.02% of the company’s stock.

Dr. Reddy’s Laboratories Trading Up 0.8 %

Shares of RDY stock opened at $72.10 on Tuesday. The company has a market capitalization of $12.03 billion, a P/E ratio of 17.89, a P/E/G ratio of 1.59 and a beta of 0.52. Dr. Reddy’s Laboratories Limited has a 12-month low of $61.25 and a 12-month high of $77.72. The company has a quick ratio of 1.92, a current ratio of 2.58 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $71.15 and a 200 day moving average price of $71.69.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its earnings results on Tuesday, May 7th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.08. The company had revenue of $850.00 million during the quarter, compared to analysts’ expectations of $825.20 million. Dr. Reddy’s Laboratories had a net margin of 19.97% and a return on equity of 21.32%. Research analysts forecast that Dr. Reddy’s Laboratories Limited will post 4.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

RDY has been the subject of a number of analyst reports. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 16th. Barclays raised their target price on Dr. Reddy’s Laboratories from $80.00 to $81.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 8th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations.